GlassScriptPhysician profile
Charles J Bennett
NPI 1639127095
$970.12
in general payments reported to CMS, 2019-2025
15 companies · $291 in 2025
The $291 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.95 · 2021: $47.53 · 2022: $86.75 · 2023: $51.75 · 2024: $474 · 2025: $291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $637 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $636.91 |
| Education | $179.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $266.29 | 2024-2025 | Xtandi |
| Dendreon Pharmaceuticals LLC | $134.50 | 2024-2025 | Provenge |
| Bayer Healthcare Pharmaceuticals INC. | $129.44 | 2022-2025 | |
| Abbvie INC. | $103.23 | 2019-2025 | Lupron Depot |
| Tolmar Pharmaceuticals, INC. | $65.13 | 2021-2022 | |
| Tolmar, INC. | $47.86 | 2023-2025 | Rubraca, Eligard |
| Blue Earth Diagnostics | $39.26 | 2024 | |
| Abbott Laboratories | $34.18 | 2024 | Amplatzer Amulet |
| Pharmaand Gmbh | $33.76 | 2025 | Rubraca |
| Novocure INC. | $25.48 | 2025 | Optune Gio |
| Sumitomo Pharma America, INC. | $22.93 | 2024 | Orgovyx |
| E.R. Squibb & Sons, L.L.C. | $20.52 | 2024 | Opdivo |
| Karl Storz Endoscopy-America | $18.04 | 2023 | N.A. |
| Smith+Nephew, INC. | $14.88 | 2021 | |
| Myovant Sciences INC. | $14.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.